Abstract 192P
Background
Lung cancer is a disease that ranks among the first in incidence and mortality in Mexico and worldwide. Neuroendocrine tumors (NETs) have been studied for their neurological and endocrine characteristics; NETs are characterized by having active autocrine/paracrine communication with the microenvironment. Serotonin is precursor of melatonin, an indolamine that can exert immunomodulatory effects and is considered one of the molecules of the neuro-immuno-endocrine axis. The transmembrane protein death ligand 1 (PD-L1) is overexpressed in some types of cancer cells, giving them the ability to camouflage themselves against the immune system. The activation PD-1/PD-L1 are responsible for the proliferation, activation, and cytotoxic secretion of T cells in cancer to generate the antitumor immune response.
Methods
In this work neuroendocrine A549 cells were obtained by two different transdifferentiation methodologies for 72 hours with cAMP inducers in DMEM with 2% fetal bovine serum (NED2%) and without fetal bovine serum (NEDsSFB). This differentiation was corroborated through the evaluation of morphology by light microscopy and the expression of specific markers Chromogranin (CgA) and Synaptophysin (Syn) by rt-PCR. The expression of PD-L1 was assessed in A549 cells, NED2% and NEDsSFB groups by rt-PCR and flow cytometry. A co-culture was performed with the neuroendocrine models with T lymphocytes to observe the cytotoxic effect for 24 hours.
Results
The results showed a new neuroendocrine model, suggest an inhibitory effect in proliferation of melatonin and serotonin from concentrations of 2.5 mM and 0.5 μM respectively in both neuroendocrine models at 24 and 48 hours. It is confirmed for the first time the presence of PD-L1 in the neuroendocrine phenotypes cells of A549 (NED2% and NEDsSFB) and thus a mechanism for evasion of the immune system can be proposed.
Conclusions
We conclude with the development of a new neuroendocrine model as well as the possible mechanism of the decrease in the cytotoxic effect of T lymphocytes in neuroendocrine models.
Legal entity responsible for the study
Universidad Autónoma de Querétaro.
Funding
Universidad Autónoma de Querétaro Conahcyt.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract